Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11th

About this update from Thiogenesis Therapeutics Corp

[{"type":"text","content":"Thiogenesis Therapeutics, Corp. to Present at the Life Sciences Virtual Investor Forum December 11thCompany invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com\n\n\n\n SAN DIEGO, Dec. 09, 2025 (GLOBE NEWSWIRE) --\n \n Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”)\n \n , a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that Brook Riggins, CFO and director, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11\n \n th\n \n .\n \n\n\n DATE\n \n : December 11\n \n th\n \n\n\n TIME: 12:00 PM ET\n \n\n\n LINK:\n \n\n\n REGISTER HERE\n \n\n\n Available for 1x1 meetings: December 17. Schedule 1x1 Meetings\n \n here\n \n\n\n This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.\n \n\n It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.\n \n\n Learn more about the event at\n \n\n www.virtualinvestorconferences.com\n \n\n .\n \n\n\n Recent Thiogenesis Highlights\n \n\n\n\n Announced Plans to file an IND for a Phase 3 cystinosis clinical trial in the US\n \n\n Reported positive data in an interim analysis of ongoing Phase 2 MELAS clinical trial in EU\n \n\n Announced clearance of IND for a Phase 2a clinical trial in Leigh syndrome spectrum in collaboration with a leading pediatric hospital in the US\n \n\n Announced EMA Confirmatory Guidance for filing an IMPD for Pediatric MASH in a proposed Phase 2 trial in EU\n \n\n\n\n About Thiogenesis Therapeutics\n \n\n\n Thiogenesis Therapeutics is a clinical-stage biopharmaceutical company with operations based in San Diego, CA. The Company is publicly traded on the TSX Venture Exchange and in the U.S. on the OTCQX. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric disease...

More updates from Thiogenesis Therapeutics Corp